With tighter aid budgets, global health is being pushed to prioritize ruthlessly: what to protect, what to cut, and who should pay. Prioritization is already a key principle in global health, evidenced by existing frameworks such as DCP3 for the cost-effectiveness of interventions or eligibility and transition policies for multilaterals like the World Bank IDA, Gavi, or the Global Fund. But prioritization is not only about what gets funded or where resources go. It is also about when financing arrives, how long it lasts, and whether support is sustained until results are achieved. This blog argues that global health doesn’t always get timing right: it can commit too late, stop too soon or even too late, as it measures the value of spending over time horizons that do not always match when benefits occur. Better timing may be one of the most overlooked ways to protect the value of global health financing.
The outcome of good prioritization should be spending the right amount on the right thing, at the right time. But this hasn’t always been the case in global health. The clock starts ticking in global health business cases and evaluations when financing decisions are made and runs until the programme cycle or political support expires. But the clock should start ticking earlier, when a high-value intervention becomes viable and unrealised gains begin accumulating; and should end when objectives are achieved sustainably. This gap between financing cycles and value realization erodes value by creating opportunity costs.
How bad timing can erode value
Bad timing can erode the value of global health investments in three ways: by acting too late, by stopping too soon, or by withdrawing too late.
In malaria control, for example, the value of artemisinin-based combination therapies relative to older drugs like chloroquine was well-known by the early 2000s. But the transition to large-scale adoption proved slow and uneven because of financing, procurement, and implementation constraints. Subsequent studies showed that delayed access to effective treatment substantially increased the risk of severe malaria and onward transmission.
Health system interventions are particularly vulnerable to stopping too soon. The experience of the West Africa Ebola epidemic of 2014 drew attention to the importance of establishing detection and response capacity, particularly in low-resource settings. The initial surge in funding was short-lived, and the shortcomings became obvious during the Covid-19 pandemic. The value of investment was clear, but the follow-through was not.
Crisis funding, on the other hand, may sometimes be prone to overstaying its welcome. If it becomes protracted, a crisis can cast an opportunity cost shadow where routine health services in the same setting may become deprioritized relative to crisis-centric services, delaying sustainability.
Global health has become adept at mobilizing attention for new causes, but not at carrying them to sustainable outcomes. This adaptation may come to bite as old agendas are resurging, such as polio, and new ones push for attention, like the new malaria vaccine. In theory, “too many agendas” isn’t a problem if decisions are made so that available resources are put to the best possible use, dynamically. In practice, however, the growing number of causes, old and new, is problematic because it erodes the credibility of global health while making prioritization and coordination politically and technically difficult.
Two complementary approaches can help the timing problem
1. In the short term, the issue should be acknowledged explicitly. Current value-for-money frameworks assess interventions within institutional cycles. But delayed adoption, interrupted financing, and failure to sustain gains can substantially alter long-run returns. This is particularly the case for health system strengthening and global public goods (GPGs) like antimicrobial resistance and pandemic preparedness, which take decades to mature and deliver returns if financing is sustained, and very little time for gains to be wiped out if financing is interrupted. Assessing value from the perspective of “value time” rather than “decision time,” that is, not only at the point of the investment decision, should become explicit in decision-making when approving global health investments.
Concretely, business cases, post-hoc evaluations and portfolio-level resource reallocations should be asking:
- What are the costs of delayed adoption or delayed scale-up?
- What are the value losses if financing is reduced or interrupted?
- What are the opportunity costs of remaining engaged—that is, can better value be created elsewhere with the same resources?
- Which investments require sustained financing, and over what time frame, to achieve their returns?
2. In the longer term, the nature of institutional mandates in global health needs to match value creation more closely. Global health currently operates in multi-year cycles—donor cycles, replenishment cycles, national strategic and budgetary cycles. GPGs, health system strengthening and, to an extent, external support for basic service delivery, are at a disadvantage because they need gradual, adaptive and predictable funding to start delivering results. Financing them based on institutional funding cycles creates tensions.
The issue is not that multilaterals or national governments do not incorporate the notion of time at all—transition policies, replenishment planning, sustainability frameworks, multi-year budgetary frameworks and other instruments account for it. What is missing is a portfolio-level view of global health so that there is accountability for delayed action and interrupted financing beyond individual institutional mandates. Existing timing failures are not oversights; they are reinforced by institutional incentives to prioritize disbursement, measurable results, and mandate-specific accountability over long-run portfolio value.
Ideally, if one institution adjusted its mandate and resource allocation, others would step in so that the overall value of the global health portfolio is not eroded. Another side of the coin relates to the coordinated scan of high value priorities in advance, fixing potential market failures, for example, advance market commitments, and preparing the long-term financing and procurement of emerging technologies and interventions so they do not displace funding at random when they arrive.
All these are difficult to do today because no single institution is responsible for optimizing the value of the global health portfolio. Such a value monitoring mechanism would undoubtedly be a GPG and its creation should be considered by the ongoing global health architecture reform conversations. Analytically, a starting point could be one of the initiatives that monitors global health financing flows, but its governance would most likely require balancing both independence from and alignment with the major global health financing stakeholders. The World Health Organization can have a strong role to play in such a mechanism should its focus sharpen towards GPGs.
Conclusion
Delayed action, unstable commitment, and failure to transition are all symptoms of the same problem with global health investments: timing currently sits outside the notion of “value.” Good timing should be treated as an integral part of value in global health investments. Making timing explicit in global health financing and aligning institutional mandates to when value can be created—as opposed to when financing decisions are made—can go some way towards fixing this problem. With much tighter budgets, global health cannot afford to treat timing as an afterthought: when money arrives and how long it lasts are part of what determines its value.
